Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Desirable drug–drug interactions or when a matter of concern becomes a renewed therapeutic strategy
Benjamin Guieu, Jean‐Pierre Jourdan, Aurore Dreneau, et al.
Drug Discovery Today (2020) Vol. 26, Iss. 2, pp. 315-328
Open Access | Times Cited: 12

Showing 12 citing articles:

Antibiotics in the clinical pipeline as of December 2022
Mark S. Butler, Ian R. Henderson, Robert J. Capon, et al.
The Journal of Antibiotics (2023) Vol. 76, Iss. 8, pp. 431-473
Open Access | Times Cited: 136
Tuberculosis Drug Discovery: Challenges and New Horizons
Guilherme Fernandes, Andrew M. Thompson, Daniele Castagnolo, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 11, pp. 7489-7531
Open Access | Times Cited: 100
A Review of Antibacterial Candidates with New Modes of Action
Mark S. Butler, Waldemar Vollmer, Emily C. A. Goodall, et al.
ACS Infectious Diseases (2024) Vol. 10, Iss. 10, pp. 3440-3474
Open Access | Times Cited: 16
DDInter: an online drug–drug interaction database towards improving clinical decision-making and patient safety
Guo‐Li Xiong, Zhijiang Yang, Jiacai Yi, et al.
Nucleic Acids Research (2021) Vol. 50, Iss. D1, pp. D1200-D1207
Open Access | Times Cited: 76
Antidepressant effects of coumarins and their derivatives: A critical analysis of research advances
Nneka Augustina Akwu, Makhotso Lekhooa, Deqiang Dou, et al.
European Journal of Pharmacology (2023) Vol. 956, pp. 175958-175958
Open Access | Times Cited: 17
The Struggle to End a Millennia-Long Pandemic: Novel Candidate and Repurposed Drugs for the Treatment of Tuberculosis
Brett Edwards, Stephen K. Field
Drugs (2022) Vol. 82, Iss. 18, pp. 1695-1715
Open Access | Times Cited: 27
Revolutionizing tuberculosis treatment: Breakthroughs, challenges, and hope on the horizon
Martin Kufa, Vladimír Finger, Ondrej Kovar, et al.
Acta Pharmaceutica Sinica B (2025)
Open Access
Synergistically Anti-Multiple Myeloma Effects: Flavonoid, Non-Flavonoid Polyphenols, and Bortezomib
Kaixi Ding, Wei Jiang, Huanan Jia, et al.
Biomolecules (2022) Vol. 12, Iss. 11, pp. 1647-1647
Open Access | Times Cited: 17
Tebipenem and Sulopenem: Dynamic Duo or Double Trouble?
Blake R. Mangum, Jason M. Pogue, Katie E. Barber
Current Infectious Disease Reports (2024) Vol. 26, Iss. 5, pp. 139-150
Open Access | Times Cited: 2
Advancements and Challenges in Tuberculosis Drug Discovery: A Comprehensive Overview
Puja Kumari Agnivesh, Arnab Roy, Shashikanta Sau, et al.
Microbial Pathogenesis (2024) Vol. 198, pp. 107074-107074
Closed Access
A host-directed oxadiazole compound potentiates antituberculosis treatment via zinc poisoning in human macrophages and in a mouse model of infection
Alexandra Maure, Emeline Lawarée, Francesco Fiorentino, et al.
PLoS Biology (2024) Vol. 22, Iss. 4, pp. e3002259-e3002259
Open Access
An oxadiazole-based compound potentiates anti-tuberculosis treatment by increasing host resistance via zinc poisoning
Alexandra Maure, Emeline Lawarée, Francesco Fiorentino, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Page 1

Scroll to top